Izračunajte točne volumene rekonstitucije, inzulinske jedinice i doze po bočici za svaki peptid.
AOD-9604 is a synthetic fragment of human growth hormone (hGH) comprising amino acids 176 to 191 of the C-terminal region. It stimulates lipolysis and inhibits lipogenesis directly in adipocytes — without activating the GH receptor, without affecting IGF-1 levels, and without influencing blood glucose or insulin sensitivity. This guide covers mechanism of action, dosage calculation, reconstitution, storage, safety, and how to combine AOD-9604 effectively with other peptides.
Medical Disclaimer: The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Peptides are not approved drugs for human use. Always consult a qualified healthcare provider before using peptides.
AOD-9604 — short for Anti-Obesity Drug 9604 — is a stabilized synthetic analog of the C-terminal fragment of human growth hormone (residues 176–191), with an additional tyrosine residue added at the N-terminus for stability. It was originally developed by researchers at Monash University in Australia in the early 2000s, following the discovery that the C-terminal region of hGH harbors most of the hormone's fat-metabolizing activity. The compound progressed through Phase II and Phase III clinical trials for obesity treatment (studied as Tyr-hGH frag 176-191) but did not receive pharmaceutical approval.
The defining pharmacological property of AOD-9604 is the separation of lipolytic activity from the growth-promoting and metabolic effects of full-length hGH. Native GH binds the GH receptor and triggers a broad hormonal cascade — muscle protein synthesis, IGF-1 elevation, altered glucose metabolism, and, with prolonged excess, acromegaly risk. AOD-9604 does none of this. It does not bind the GH receptor, does not raise IGF-1, does not affect blood glucose, and has no anabolic properties. Its activity is essentially confined to adipocyte metabolism, making it a uniquely targeted tool in metabolic research.
AOD-9604 promotes fat loss through two complementary adipocyte-level mechanisms:
The precise receptor through which AOD-9604 mediates these effects is not yet fully characterized. Research evidence suggests interaction with beta-3 adrenergic receptors on adipocytes and possibly with a distinct fragment-specific receptor on the adipocyte surface, though the complete molecular picture remains an active area of investigation. What is well-established from clinical data is that these effects occur independently of the GH receptor and without altering systemic hormone levels.
In animal studies, AOD-9604 consistently reduced body fat without:
Standard dosing parameters for AOD-9604 are:
AOD-9604 does not require a gradual dose escalation. The standard dose is used from the first injection. Some practitioners favor starting at 250 mcg daily for the first week purely as a tolerance assessment measure, then moving to 300 mcg.
The standard BergdorfBio AOD-9604 vial contains 5 mg of lyophilized peptide. Adding 2 ml of bacteriostatic water (BAC water) gives a concentration of:
5 mg ÷ 2 ml = 2.5 mg/ml = 2,500 mcg/ml
Using a 0.3 ml U100 insulin syringe (100 units = 1 ml):
At 300 mcg daily, one 5 mg vial lasts approximately 16 days. At 500 mcg daily, the same vial lasts approximately 10 days.
With 2 mg peptide and 2 ml BAC water, the concentration is 1 mg/ml (1,000 mcg/ml):
Use the BergdorfBio Peptide Calculator for instant volume calculations with any vial size, reconstitution volume, and target dose — it outputs the precise draw volume in milliliters and insulin units.
AOD-9604 is typically injected in the morning, fasted. Elevated post-meal insulin levels can blunt lipolytic signaling, so a fasted state — or at minimum 2 hours after any meal — is preferred. Pre-workout injection (20–30 minutes before training) is also used by some protocols. Because AOD-9604 does not trigger systemic GH release, timing is less critical than for GHRH/GHRP peptides, but the fasted window remains the standard recommendation.
AOD-9604 is supplied as a lyophilized powder and must be reconstituted before injection. You will need:
Use only bacteriostatic water or sterile water for injection (WFI). Do not use tap water, commercially purchased distilled water, or saline solutions not specifically labeled for injection use.
AOD-9604 has one of the most favorable safety profiles among metabolic peptides studied in clinical trials. Because it does not activate the GH receptor or alter systemic hormone levels, many of the risks associated with full-length hGH or potent GH secretagogues are not present.
Unlike full-length hGH, AOD-9604 does not cause fluid retention, carpal tunnel symptoms, insulin resistance, elevated fasting blood glucose, or IGF-1 elevation. There is no acromegaly risk. In Phase II and Phase III clinical trials, the adverse event profile of AOD-9604 was comparable to placebo. This distinguishes it fundamentally from synthetic growth hormone and makes it an attractive candidate for researchers requiring targeted lipolytic intervention without systemic hormonal consequences.
Discontinue use and consult a physician if you experience persistent nausea, severe headache, unusual swelling, allergic symptoms (rash, difficulty breathing, facial swelling), or any other concerning reactions.
The combination of AOD-9604 with CJC-1295 No DAC is logical for researchers targeting both systemic GH axis stimulation and direct adipocyte lipolysis. CJC-1295 No DAC drives pulsatile GH secretion from the pituitary, which elevates IGF-1 and produces a broad anabolic and metabolic response. AOD-9604 complements this through an independent, peripheral lipolytic mechanism that operates without involving GH receptors or IGF-1 signaling. There is no pharmacological overlap or competition between the two peptides.
Adding AOD-9604 to an Ipamorelin protocol creates a two-pathway approach to fat metabolism. Ipamorelin activates GHS-R1a receptors to stimulate pulsatile GH release from the pituitary — indirectly supporting body recomposition via IGF-1 and GH-mediated lipolysis. AOD-9604 contributes a direct, IGF-1-independent lipolytic effect at the adipocyte level. The two mechanisms are non-competitive and target fat loss through distinct biological routes.
The full GH peptide stack combines GHRH receptor activation (CJC-1295 No DAC), GHS-R1a stimulation (Ipamorelin), and direct adipocyte lipolysis (AOD-9604). Each component contributes through a non-redundant mechanism: the first amplifies pituitary GH output via the GHRH pathway, the second amplifies it further via the ghrelin receptor pathway, and the third acts peripherally on fat cells independently of the GH axis. For researchers studying body recomposition and recovery, this stack covers the available mechanistic space comprehensively. Physician supervision and baseline lab work (IGF-1, fasting glucose) are especially important with multi-peptide protocols.
AOD-9604 is available at BergdorfBio in 2 mg and 5 mg research-grade vials with verified purity and identity testing.
Full-length hGH binds the GH receptor and initiates a broad hormonal cascade — muscle protein synthesis, IGF-1 elevation, altered glucose metabolism, fluid retention, and, with chronic excess, acromegaly. AOD-9604 is a 16-amino-acid fragment (residues 176–191) that does not bind the GH receptor and therefore triggers none of these systemic effects. Its activity is restricted to adipocyte fat metabolism, making it a far more targeted intervention with a substantially better safety profile compared to synthetic GH.
No. This is one of the best-documented properties of AOD-9604. Clinical studies confirmed no measurable change in serum IGF-1 concentrations following AOD-9604 administration. For individuals with specific reasons to avoid IGF-1 elevation — including those in competitive sports, those with insulin-related concerns, or those monitoring oncological risk factors — this is an important distinction.
No. Unlike full-length hGH, which can reduce insulin sensitivity at supraphysiological doses, AOD-9604 demonstrated no effect on fasting blood glucose, insulin sensitivity, or glucose tolerance in clinical trials. This makes it meaningfully safer than synthetic GH for metabolic research, particularly in individuals with pre-existing glucose metabolism concerns.
Morning injection in a fasted state is the standard recommendation, as post-meal insulin elevations can attenuate lipolytic signaling. Pre-workout injection (approximately 20–30 minutes before training) is used by some protocols to coincide the peptide's lipolytic activity with exercise-induced fat oxidation. Because AOD-9604 does not affect GH pulse timing, the strict fasting windows required for GHRH/GHRP peptides are less critical here — though fasted injection remains best practice.
Most protocols use 8–12 weeks of daily administration followed by a 4-week break. Some researchers report running 16-week cycles, though long-term human data beyond the original clinical trials is limited. Cycle breaks are a conservative measure to prevent potential receptor adaptation and allow periodic evaluation of outcomes.
No specific dietary requirements are documented for AOD-9604. However, since the compound works by promoting fat breakdown and inhibiting fat storage, pairing it with a moderate caloric deficit and a diet that keeps post-meal insulin spikes manageable will support its mechanism. Fasted morning injection is recommended regardless of broader dietary approach.
CJC-1295 No DAC stimulates pituitary GH release, which promotes fat oxidation indirectly through elevated IGF-1 and GH's metabolic effects on adipose tissue. AOD-9604 acts directly on adipocytes through a receptor distinct from the GH receptor, independent of systemic GH or IGF-1 changes. CJC-1295's fat-loss effects are part of a broader hormonal response; AOD-9604's are specific and isolated to adipocyte metabolism. The mechanisms are complementary rather than equivalent, which is why combining them can produce outcomes neither peptide achieves independently.
Physician consultation is always recommended before beginning any peptide protocol. While AOD-9604 has a relatively benign safety profile, ruling out contraindications, reviewing current medications for potential interactions, and establishing baselines (body composition, fasting glucose, lipid panel) are best-practice steps that require clinical assessment.
BergdorfBio offers AOD-9604 in verified research quality in both 2 mg and 5 mg vials. Each batch is tested for identity and purity. Visit the product page for current availability and pricing.
Disclaimer: This content is for informational and research purposes only. AOD-9604 is not an approved drug for human therapeutic use. The applications described have not been evaluated or approved by the FDA, EMA, or any other regulatory authority. Do not use peptides without the supervision of a qualified medical professional.
Pogledajte proizvod
AOD-9604